DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
6th & Kipling St. (P.O. Box 25087)	2/12/2018-2/23/2018*			
Denver, CO 80225-0087	FEI NUMBER			
(303)236-3000 Fax: (303)236-3100	3013438582			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	·			
Christopher F. Zuccarelli, COO				
FIRM NAME	STREET ADDRESS			
Denver Solutions, LLC DBA Leiter's	13796 Compark Blvd			
Health	1.50			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Englewood, CO 80112-7145	outsourcing facility			

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

Drug products failing to meet established quality control criteria are not rejected.

Specifically, on 02/14/18, I observed an unidentified black material imbedded into the wall of two filled syringes from Phenylephrine HCl injection, 100 mcg/mL, lot 1730021. The firm's approved visual inspection process failed to detect the defects. One syringe was in the released inventory and the other was a reserve sample.

OBSERVATION 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

2A) On 02/14/18, I observed the QC Supervisor did not perform surface sampling of all equipment I observed used during production on 02/13/18. The QC supervisor failed to follow the approved sampling procedure and the procedure did not include adequate instructions. Further questioning revealed the following:

SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Nicholas L Hunt,	Investigator	Nicholas L Hunt Investigator Signed By Nicholas L Hunt-S Date Signed 02-23-2018 13 37 49	2/23/2018
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 1 OF 3 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
6th & Kipling St. (P.O. Box 25087)	2/12/2018-2/23/2018*			
Denver, CO 80225-0087 (303)236-3000 Fax:(303)236-3100	3013438582			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED				
Christopher F. Zuccarelli, COO	w m			
FIRM NAME	STREET ADDRESS			
Denver Solutions, LLC DBA Leiter's	13796 Compark Blvd			
Health				
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Englewood, CO 80112-7145	outsourcing facility			

- -- The QC Supervisor confirmed the material cart I observed used to hold components prior to introduction into the ISO 5 hood does not get sampled. The material cart was moved throughout ISO 7 Room (b) (4) as needed during production.
- -- The QC Supervisor confirmed one of two tables in the middle of the room, which was used extensively throughout production, does not get sampled. I observed the table used to stage materials, write in logbooks, and other functions during production.
- -- The QC Supervisor confirmed there was no way to ensure all equipment in the ISO 7 room was sampled when there are multiple units, per the approved surface sampling procedure. Support equipment such as chairs, production carts, material carts, and tables lacked unique identification markings.
- 2B) The firm had inadequate justification for their non-viable air monitoring procedures inside the ISO 5 areas. The firm's approved environmental monitoring procedure and building management system parameters do not require an investigation until (b) (4) readings above the action limit for non-viable air. (b) (4) readings correspond to a (b) (4) time interval.

OBSERVATION 3

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.

Specifically, on 12/06/17, production personnel failed to perform the (b) (4) clean process for ISO 7 Rooms (b) (4) and (b) (4) after an extended loss of differential pressure. The walls, doors/ door frames, windows/ window frames, ceilings, and light fixtures were not disinfected per the approved procedure. Room (b) (4) is the (b) (4) where the ISO 5 hoods are located for aseptic processing operations. Operators moved materials through the improperly cleaned Room (b) (4) into Room (b) (4) to produce Phenylephrine HCl injection, 100 mcg/mL, lot 1730020 on 12/06/17.

SEE REVERSE OF THIS PAGE	employee(s) Signature Nicholas L Hunt, I	nvestigator	Nicholas L Hunt Investigator System Nicholas L Hunt -S Date Signed 02-23-2018 13 37 49	DATE ISSUED 2/23/2018
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIO	NS	PAGE 2 OF 3 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION		
6th & Kipling St. (P.O. Box 25087)	2/12/2018-2/23/2018*		
Denver, CO 80225-0087 (303)236-3000 Fax:(303)236-3100	3013438582		
2 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.0			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED			
Christopher F. Zuccarelli, COO	W 10		
FIRM NAME	STREET ADDRESS		
Denver Solutions, LLC DBA Leiter's	13796 Compark Blvd		
Health	559		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Englewood, CO 80112-7145	outsourcing facility		
	¥		

OBSERVATION 4

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, Operator performed aseptic filling for finished product lots 1730020, 1730021, 1830003, 1830015, 1830018, and 1830020 before he completed his gowning qualification on 02/13/18. No deviation was initiated per the approved procedure, and there was no assessment of the potential impact to the finished product lots.

*DATES OF INSPECTION

2/12/2018(Mon), 2/13/2018(Tue), 2/14/2018(Wed), 2/15/2018(Thu), 2/16/2018(Fri), 2/21/2018(Wed), 2/22/2018(Thu), 2/23/2018(Fri)

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Nicholas L Hunt, Invest	tigator	Nicholas L Hunt Investigator Stigned By Nicholas L. Hunt -S Date Signed 02-23-2018 13 37 49	DATE ISSUED 2/23/2018

FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 3 OF 3 PAGES